Stakeholders want more collaboration, regulatory flexibility in FDA’s new rare disease hub
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesOrphan drugsPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)